A review of the pharmacology and pharmacotherapy of colony-stimulating factors

Journal of Infusion Nursing

Volumn 31, Issue 5, 2008, Pages 295-306

  Throm, Melinda J ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLONY STIMULATING FACTOR; COTRIMOXAZOLE; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ILLICIT DRUG; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; STAVUDINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE HEART INFARCTION; ADULT RESPIRATORY DISTRESS SYNDROME; ALLERGIC REACTION; ANEMIA; ARTHRALGIA; BLEEDING; BONE PAIN; CARDIOVASCULAR DISEASE; CHILL; CHRONIC KIDNEY DISEASE; CONTINUOUS INFUSION; CROHN DISEASE; DEATH; DIABETIC FOOT; DIARRHEA; DOPING; DRUG ACTIVITY; DRUG INDICATION; DRUG WITHDRAWAL; DYSPNEA; FACE EDEMA; FEVER; FLU LIKE SYNDROME; HEADACHE; HEART ARREST; HEART FAILURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPOTENSION; INFECTION; JEHOVAH'S WITNESS; MEDICATION ERROR; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; NURSE; NURSING CARE; ONCOLOGY; PATIENT EDUCATION; PATIENT MONITORING; PRESCRIPTION; PRIORITY JOURNAL; RASH; RESPIRATORY TRACT DISEASE; REVIEW; SEIZURE; SICKLE CELL CRISIS; SIDE EFFECT; SKIN MANIFESTATION; SPLEEN RUPTURE; STROKE; TACHYCARDIA; THROMBOCYTOPENIA; THROMBOSIS; URTICARIA; VASCULITIS; VOMITING; WHEEZING; WOUND; WOUND HEALING; MONITORING; NURSING;

COLONY-STIMULATING FACTORS; HUMANS; MONITORING, PHYSIOLOGIC; NURSING; PATIENT EDUCATION AS TOPIC;

EID: 58149133783     PISSN: 15331458     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.NAN.0000336184.85280.79     Document Type: Review

References (50)

1. Adams VR. Adverse events associated with chemotherapy for common cancers. Pharmacotherapy. 2000;20(7, pt 2): 96S-103S.
2. Valley AW. Overview of cancer-related anemia: focus on the potential role of darbepoetin alfa. Pharmacotherapy. 2002;22(9, pt 2):150S-159S.
3. Kuhn JG. Chemotherapy-associated hematopoietic toxicity. Am J Health Syst Pharm. 2002;59(suppl 4):S4-S7.
4. Tristram G, ed. Medical Immunology. 10th ed. New York, NY: Lange Medical Books/McGraw-Hill Medical Publishing Division; 2001. STATRef Online Electronic Medical Library. http://online.statref.com/document.aspx?fxid=22&docid=1. Accessed October 15, 2007.
5. Poole SK, Nowobilski-Vasilios A. Trends in the use of colony-stimulating factors. J Infus Nurs. 2006;29(3):151-157.
6. Montoya L. Managing hematologic toxicities in the oncology patient. J Infus Nurs. 2007;30(3):168-172.
7. National Comprehensive Cancer Network. Practice Guidelines in Oncology. Prevention and Treatment of Cancer-Related Infections. Vol 1. Fort Washington, PA: National Comprehensive Cancer Network; 2007. http://www.nccn.org/ professionals/physician-gls/PDF/fever.pdf. Accessed October 15, 2007.
8. Neupogen® (filgrastim) [package insert]. Thousand Oaks, CA: Amgen Inc; 2007.
9. Neulasta® (pegfilgrastim) [package insert]. Thousand Oaks, CA: Amgen Inc; 2007.
10. Leukine® (sargramostim) [package insert]. Seattle, WA: Berlex; 2006.
11. Sylvester RK. Clinical applications of colony-stimulating factors: a historical perspective. Am J Health Syst Pharm. 2002;59(suppl 2):S6-S12.
12. Kleinberg M, Mosdell KW. Current and future considerations for the new classes of biologicals. Am J Health Syst Pharm. 2004;61:695-710.
13. Lexi-Comp Online™, Lexi11-Drugs Online™. Hudson, Ohio: Lexi-Comp, Inc.; 2007. Accessed October 15, 2007.
14. Molineus G. Pegylation: engineering improved biopharma-ceuticals for oncology. Pharmacotherapy. 2003;23(8, pt 2): 3S-8S.
15. Petros WP. Introduction: pegfilgrastim, a new era in the management of chemotherapy-induced neutropenia. Pharmacotherapy. 2003:23(8, pt 2):1S-2S.
16. Zamboni WC. Pharmacokinetics of pegfilgrastim. Pharmacoth erapy. 2003;23(8, pt 2):9S-14S.
17. Infection Protection with Leukine®. A guide for patients. Wayne, NJ: Bayer Healthcare Pharmaceuticals; April 2007.
18. Cosby CD. Hematologic disorders associated with human immunodeficiency virus and AIDS. J Infus Nurs. 2007;30(1):22-32.
19. Engles-Horton LL, Skowronski C, Mostashari F, Altice FL. Clinical guidelines and pharmacist intervention program for HIV-infected patients requiring granulocyte colony-stimulating factor therapy. Pharmacotherapy. 1999;19(3):356-362.
20. Centers for Disease Control and Prevention. Guidelines for preventing opportunistic infections among HIV-infected persons-2002: recommendations of the U. S. Public Health Service and the Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep. 2002;51(RR-8):1-52.
21. Centers for Disease Control and Prevention. Treating opportunistic infections among HIV-infected adults and adolescents: recommendations from the CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. MMWR Morb Mortal Wkly Rep. 2004;53(RR-15): 1-112.
22. Korzenik JR, Dieckgraefe BK, Valentine JF, et al. Sargramostim for active Crohn's disease. New Engl J Med. 2005;352: 2193-2201.
23. Chiappelli F. The molecular immunology of mucositis: implications for evidence-based research in alternative and complementary palliative treatments. Evid Based Complement Alternat Med. 2005;2(4):489-494.
24. Kwong KK. Prevention and treatment of oropharyngeal mucositis following cancer therapy. Are there new approaches? Cancer Nurs. 2004;27(3):183-205.
25. Keefe DM, Schubert MM, Elting LS, et al. Updated practice guidelines for the prevention and treatment of mucositis. Cancer. 2007;109:820-831.
26. American Diabetes Association. Preventive foot care in diabetes. Diabetes Care. 2004;27(suppl 1):63S-64S.
27. Cruciani M, Lipsky BA, Mengoli C, de Lalla F. Are granulocyte colony-stimulating factors beneficial in treating diabetic foot infections? A meta-analysis. Diabetes Care. 2005;28:454-460.
28. National Comprehensive Cancer Network (NCCN) Practice guidelines in oncology. Cancer-and treatment-related anemia. Version 3. 2007. http://www.nccn.org/professionals/physician-gls/PDF/anemia.pdf. Published April 10, 2007. Accessed October 21, 2007.
29. US Department of Health and Human Services, Department of Medicare and Medicaid Services. Proposed decision memo for ery-thropoiesis stimulating agents (ESAs) for non-renal disease indications (CAG-00383N) [memorandum, May 14, 2007]. https://www.cms.hhs.gov/. Accessed February 24, 2008.
30. Epogen® (epoetin alfa) [package insert]. Thousand Oaks, CA: Amgen Inc; 2007.
31. Procrit® (epoetin alfa) [package insert]. Raritan, NJ: Ortho Biotech; 2007.
32. Aranesp® (darbepoetin alfa) [package insert]. Thousand Oaks, CA: Amgen Inc; 2007.
33. Overbay DK, Manley HJ. Darbepoetin-alpha: a review of the literature. Pharmacotherapy. 2002;22(7):889-897.
34. Zamboni WC, Stewart CF. An overview of the pharmacokinetic disposition of darbepoetin alfa. Pharmacotherapy. 2002;22(9, pt 2):133S-1340S.
35. Scott SD. Dose conversion from recombinant human erythropoietin to darbepoetin alfa: recommendations from clinical studies. Pharmacotherapy. 2002;22(9, pt 2):160S-65S.
36. Stevenson JG, Natale JJ. Darbepoetin alfa: an effective treatment with flexible and simplified dosing for anemia in patients with cancer. Pharmacotherapy. 2007;27(3):434-446.
37. The growing demand for bloodless medicine and surgery. Watch Tower Bible and Tract Society of Pennsylvania. http://www.watch-tower.org/e/20000108/ article-03.htm. Accessed October 21, 2007.
38. Remmers PA, Speer AJ, Wazny LD, et al. Clinical strategies in the medical care of Jehovah's Witnesses. Am J Med. 2006;119(12): 1013-8101.
39. Doyle JD. Blood transfusions and the Jehovah's Witness patient. Am J Ther. 2002;9(5):417-424.
40. Oprelvekin or interleukin-11 (Neumega®) [package insert]. Philadelphia, PA: Wyeth; 2006.
41. Wazny LD, Ariano RE. Evaluation and management of drug-induced thrombocytopenia in the acutely ill patient. Pharmacotherapy. 2000;20(3):292-307.
42. Infusion Nurses Society. Infusion nursing standards of practice. J Infus Nurs. 2006;29(suppl 1):S1-S92.
43. Infusion Nurses Society. Policies and Procedures for Infusion Nursing. 3rd ed. Norwood, MA: Infusion Nurses Society; 2006.
44. Neupogen® (filgrastim) information for patients and caregivers [package insert]. Thousand Oaks, CA: Amgen Inc; 2006.
45. Neulasta® (pegfilgrastim) information for patients and caregivers [package insert]. Thousand Oaks, CA: Amgen Inc; 2007.
46. Leukine (sargramostim) [package insert]. Seattle, WA: Berlex; 2007.
47. Epogen® (epoetin alfa) [patient insert]. Thousand Oaks, CA: Amgen Inc; 2007/03/2007.
48. Procrit® (epoetin alfa) [patient insert]. Raritan, NJ: Ortho Biotech; 2007.
49. Aranesp® (darbepoetin alfa) [patient insert]. Thousand Oaks, CA: Amgen Inc; 2007.
50. Oprelvekin or interleukin-11 (Neumega®) [patient insert]. Philadelphia, PA: Wyeth; 2006.